Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B/F/TAF switch in virologically suppressed HIV-1 adults in Haiti
NCT04311957Phase 4Unknown
- Sponsor
- GHESKIO
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by GHESKIO. Primary endpoint: Virologic failure - 200 Copies/mL cut-off at 48 weeks. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04311957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311957.